Quotient Bioresearch has acquired Amersham Radiolabelling Services, the radiochemical custom synthesis operations of GE Healthcare.
Amersham Radiolabelling Services custom synthesises carbon-14 and tritium labelled compounds for the pharmaceutical and biotechnology industries.
The operations and staff of Amersham Radiolabelling Services will combine with the radiochemistry and metabolism activities of Quotient Bioresearch to form a new strategic business unit - Quotient Chemistry and Metabolism.
This integrated service will simplify the procurement of regulatory and non-regulatory studies, resulting in shorter development times and associated efficiencies.
The enlarged Quotient business will offer the following services: manufacture of custom radio-labelled drug compounds; a full range of in vivo and in vitro metabolism studies covering all FDA guidelines; clinical studies, including human AME studies, IVmicrotracer and Phase 0 microdosing studies; and a broad range of bioanalytical services.
From today, the global sales operations will transfer to Quotient, with the tritium and carbon-14 radiolabelling services transferring to Quotient by the end of 2009 and March 2010 respectively.